SANOFI PASTEUR
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Subsidiary
- Established
- 1990-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.sanofipasteur.com
A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination
Phase 4
Completed
- Conditions
- Influenza
- Interventions
- Biological: Split, Inactivated, Trivalent Influenza vaccine (Fluzone®)
- First Posted Date
- 2008-08-28
- Last Posted Date
- 2016-05-16
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 120
- Registration Number
- NCT00743275
Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults
Phase 2
Completed
- Conditions
- Dengue FeverDengue Hemorrhagic FeverDengue VirusDengue Diseases
- Interventions
- Biological: Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero)Biological: Tetravalent blending VDV-2/CYD-1,3,4 Dengue (Vero)Biological: Tetravalent CYD-1,2,3,4 Dengue (Vero)
- First Posted Date
- 2008-08-22
- Last Posted Date
- 2015-03-03
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 154
- Registration Number
- NCT00740155
Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines
Phase 3
Completed
- Conditions
- Hepatitis AJapanese Encephalitis
- Interventions
- Biological: Japanese encephalitis vaccineBiological: Japanese encephalitis vaccine (Acambis)Biological: Hepatitis A vaccine
- First Posted Date
- 2008-08-15
- Last Posted Date
- 2015-04-21
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 1200
- Registration Number
- NCT00735644
36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds
Completed
- Conditions
- MeningitisMeningococcal Disease
- Interventions
- Biological: None administered in this study
- First Posted Date
- 2008-08-05
- Last Posted Date
- 2015-02-12
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 1421
- Registration Number
- NCT00728260
Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation
Phase 2
Completed
- Conditions
- InfluenzaOrthomyxoviridae Infections
- Interventions
- Biological: Split virion, inactivated Influenza vaccine
- First Posted Date
- 2008-07-18
- Last Posted Date
- 2014-01-17
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 130
- Registration Number
- NCT00718146
Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose
Phase 4
Completed
- Conditions
- PertussisTetanusDiphtheria
- Interventions
- Biological: Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)
- First Posted Date
- 2008-07-10
- Last Posted Date
- 2014-04-30
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 769
- Registration Number
- NCT00712959
Study of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route Versus Vaxigrip® in Adults
Phase 2
Completed
- Conditions
- InfluenzaOrthomyxoviridae InfectionMyxovirus Infection
- Interventions
- Biological: Inactivated, split-virion influenza vaccine
- First Posted Date
- 2008-06-23
- Last Posted Date
- 2014-01-13
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 1150
- Registration Number
- NCT00703651
Dose Comparison Study of Menactra® in US Children
Phase 2
Completed
- Conditions
- Neisseria MeningitidisMeningitisMeningococcal Infection
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 333
- Registration Number
- NCT00700635
Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26
Phase 2
Completed
- Conditions
- MeningitisMeningococcemia
- Interventions
- Biological: Meningococcal polysaccharide diphtheria toxoid conjugate
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2016-02-15
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 181
- Registration Number
- NCT00700713
A Study to Assess the Anamnestic Immune Response in Healthy 4 to 7 Year-old Children After a Primary Vaccination Series With Either HEXAVAC® or INFANRIX®-HEXA
Phase 3
Completed
- Conditions
- Hepatitis B
- Interventions
- Biological: Engerix B® 10 µg / 0.5 mLBiological: HBVaxPRO® 5 µg / 0.5 mL
- First Posted Date
- 2008-06-06
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 410
- Registration Number
- NCT00693186
- Locations
- 🇮🇹
Unità Operativa Semplice di Epidemiologia (UOSE), Quarto, Napoli, Italy
🇮🇹Azienda per i Servizi Sanitari n. 5 "Bassa Friulana", Latisana, Udine, Italy
🇮🇹Ospedale Maggiore di Modica - Via Resistenza Partigiana (c/o Ospedale Maggiore), Modica, Italy
© Copyright 2025. All Rights Reserved by MedPath